MADISON, Wisc.--(BUSINESS WIRE)--Invenra’s collaboration partner, Exelixis, Inc. (NASDAQ: EXEL) has announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XB010 in patients with locally advanced or metastatic solid tumors.

威斯康星州麦迪逊市。-（商业新闻短讯）--Invenra的合作伙伴Exelixis，Inc.（纳斯达克股票代码：EXEL）宣布开始XB010在局部晚期或转移性实体瘤患者中首次人体1期临床试验的剂量递增阶段。

XB010, an antibody-drug conjugate (ADC) consisting of a monomethyl auristatin E payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4, is the first custom ADC generated through Exelixis’ biotherapeutics collaboration network. XB010 was constructed using Catalent’s SMARTag site-specific bioconjugation platform, and its 5T4-targeting mAb was discovered in collaboration with Invenra..

XB010是一种抗体-药物偶联物（ADC），由与靶向肿瘤抗原5T4的单克隆抗体偶联的单甲基auristatin E有效载荷组成，是通过Exelixis的生物治疗合作网络生成的第一个定制ADC。XB010是使用Catalent的SMARTag位点特异性生物缀合平台构建的，其5T4靶向mAb是与Invenra合作发现的。。

Exelixis further announced that the dose-escalation stage of their phase 1, global, open-label study will evaluate XB010 as a single agent and in combination with pembrolizumab to inform the cohort-expansion stage. The expansion cohorts are designed to further assess the tolerability and activity of monotherapy and of the combination in specific indications..

Exelixis进一步宣布，他们的第一阶段全球开放标签研究的剂量递增阶段将评估XB010作为单一药物，并与pembrolizumab联合使用，以告知队列扩展阶段。。。